Margaux P.
- Country
- Belgium
- Department
- Neurology
Research Overview
- Phase 2a Study to Evaluate the Safety and Efficacy of Empasiprubart as Add-on Therapy to Efgartigimod in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Phase 2a Randomized Double‑Blind Placebo‑Controlled Study of Empasiprubart IV Monotherapy in AChR‑Ab Seropositive Generalized Myasthenia Gravis
- Efficacy and Safety Evaluation of Efgartigimod Alfa in Adults with Ocular Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Data & Insights
Has run more than one trial at 18 of 41 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in the study of ocular myasthenia gravis, a rare autoimmune neuromuscular disorder affecting the eye muscles and causing visual symptoms.
- Vision-related neuromuscular conditions
- Autoimmune neuromuscular disorders
- Ocular muscle weakness management
The research focuses on evaluating innovative therapeutic approaches for patients with ocular manifestations of myasthenia gravis.
Therapeutic Development
Active involvement in advancing treatment options for neuromuscular junction disorders, with particular emphasis on subcutaneous therapeutic applications.
- Novel therapeutic compounds
- Subcutaneous drug delivery
- Treatment efficacy assessment
The investigator evaluates new therapeutic compounds targeting specific autoimmune mechanisms in ocular disorders.
Clinical Assessment
Expertise in conducting clinical evaluations of targeted therapies for patients with autoimmune neuromuscular conditions affecting ocular function.
- Safety monitoring protocols
- Efficacy measurements
- Patient outcome assessment
Research activities include systematic evaluation of therapeutic interventions in neuromuscular disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.